Developmental toxicity of artesunate in the rat: comparison to other artemisinins, comparison of embryotoxicity and kinetics by oral and intravenous routes, and relationship to maternal reticulocyte count
- 13 August 2008
- journal article
- research article
- Published by Wiley in Birth Defects Research Part B: Developmental and Reproductive Toxicology
- Vol. 83 (4) , 397-406
Abstract
BACKGROUND: The antimalarial, artesunate, is teratogenic and embryolethal in rats, with peak sensitivity on Days 10 and 11 postcoitum (pc). METHODS: We compared the developmental toxicity of structurally related artemisinins, dihdyroartemisinin (DHA), artemether (ARTM), and arteether (ARTE) to that of artesunate after oral administration to rats on Day 10 pc. In separate studies, embryolethality was characterized after single intravenous (IV) administration of artesunate on Day 11 pc, and toxicokinetic parameters following oral and IV administration were compared. Lastly, to determine whether maternal hematologic effects occurred at doses that affect embryonic erythroblasts, artesunate was orally administered on Day 11 pc at a dose that caused 100% embryolethality. RESULTS: All artemisinins caused the same pattern of embryolethality and fetal cardiovascular and skeletal abnormalities as previously shown for artesunate. In the IV study, marked postimplantation loss occurred at 1.5 and 3 mg/kg artesunate, but not at 0.75 mg/kg. Among the toxicokinetic parameters evaluated, only the DHA AUC0‐t was similar at embryolethal oral and IV doses of artesunate. An embryolethal dose of artesunate caused a 15% decrease in maternal reticulocyte counts and no other hematologic effects. CONCLUSIONS: Several structurally related artemisinins cause similar developmental toxicity, suggesting an artemisinin class effect. Equally embryotoxic oral and IV treatments of one artemisinin compound (artesunate) produced similar systemic exposure to the artesunate metabolite, DHA, suggesting that DHA may be the proximate developmental toxicant. Embryolethal doses of artesunate only caused minor changes in maternal reticulocyte counts indicating that adult hematology parameters are not as sensitive as embryonic erythroblasts. Birth Defects Res (Part B) 83:397–406, 2008.Keywords
This publication has 11 references indexed in Scilit:
- Investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) using the Frog Embryo Teratogenesis Assay-Xenopus (FETAX)Reproductive Toxicology, 2008
- Sensitive periods for developmental toxicity of orally administered artesunate in the ratBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2008
- In vivo and in vitro investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryosReproductive Toxicology, 2006
- Artesunate-induced depletion of embryonic erythroblasts precedes embryolethality and teratogenicity in vivoBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2006
- Effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos in vitroReproductive Toxicology, 2006
- Developmental toxicity of artesunate and an artesunate combination in the rat and rabbitBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2004
- Spontaneous and induced alterations in the cardiac membranous ventricular septum of fetal, weanling, and adult ratsTeratology, 1997
- Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy.Microbiological Reviews, 1996
- Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivativesTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994
- An Approximate Distribution of Estimates of Variance ComponentsBiometrics Bulletin, 1946